Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)-Reference-Cited by-同舟云学术

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Published:2019-10 Issue: Volume:30 Page:v485-v486
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Drew Y.,Kaufman B.,Banerjee S.,Lortholary A.,Hong S.H.,Park Y.H.,Zimmermann S.,Roxburgh P.,Ferguson M.,Alvarez R.H.,Domchek S.,Gresty C.,Angell H.K.,Ros V Rocher,Meyer K.,Lanasa M.,Herbolsheimer P.,de Jonge M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz253.016/30084552/mdz253.016.pdf

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers;British Journal of Cancer;2024-07-06

2. Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors;Biomedicine & Pharmacotherapy;2024-06

3. Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy;Immunology;2024-04-15

4. BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges;Frontiers in Oncology;2024-03-13

5. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group;Nature Communications;2024-03-05